Description
The National Institutes of Health (NIH) is seeking to purchase twenty (20) Infinium Methylation Screening Array-48 Kits (Catalog No. 20112611) from Illumina, Inc. The kits will be used to conduct an epigenome-wide association study (EWAS) of DNA methylation patterns and cardiovascular disease (CVD) mortality risk using excess biospecimens from the NCI Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. The kits must meet specific salient characteristics, including approximately 270,000 CpG methylation sites interrogated and compatibility with the Illumina iScan System and Infinium Automated Pipetting System with ILASS.
Key features of the requirement include:
• The kits must be delivered to the NIH NIA Laboratory of Neurogenetics as soon as possible following award, but no later than December 30, 2026.
• The contract will be awarded on a non-competitive basis to Illumina, Inc.
• The acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services.
• The associated NAICS code is 325413 – In-Vitro Diagnostic Substance Manufacturing.